GPCR — Structure Therapeutics Cashflow Statement
0.000.00%
- $1.83bn
- $1.39bn
- 30
- 26
- 35
- 20
Annual cashflow statement for Structure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -15.9 | -38 | -51.3 | -89.6 |
Depreciation | ||||
Non-Cash Items | 0.647 | 1.75 | 1.96 | 2.87 |
Other Non-Cash Items | ||||
Changes in Working Capital | 0.946 | 4.06 | 2.97 | 6.97 |
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Cash from Operating Activities | -14.3 | -32.2 | -46.1 | -79.5 |
Capital Expenditures | -0.019 | -1.21 | -0.155 | -2.17 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | -21.1 | 19.1 | -62 | -266 |
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Cash from Investing Activities | -21.1 | 17.9 | -62.1 | -268 |
Financing Cash Flow Items | 0 | -0.115 | -2.52 | -21.6 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Cash from Financing Activities | 25.8 | 103 | 29 | 452 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -9.59 | 89 | -79.2 | 104 |